About Biomodal
Biomodal is a company based in Cambridge (United Kingdom) founded in 2012. Biomodal has raised $164.1 million across 5 funding rounds from investors including Syncona, Temasek and European Union. Biomodal offers products and services including duet multiomics solution evoC and duet multiomics solution +modC. Biomodal operates in a competitive market with competitors including Aligned Bio, Singular Bio, YouScript, Nooma Bio and Annogen, among others.
- Headquarter Cambridge, United Kingdom
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$164.1 M (USD)
in 5 rounds
-
Latest Funding Round
$88 M (USD), Series D
Nov 02, 2021
-
Investors
Syncona
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biomodal
Biomodal offers a comprehensive portfolio of products and services, including duet multiomics solution evoC and duet multiomics solution +modC.
Enables 6-base genome sequencing from single DNA samples.
Assesses canonical bases and modified cytosine in one experiment.
Funding Insights of Biomodal
Biomodal has successfully raised a total of $164.1M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $88 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biomodal
Biomodal has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, Temasek and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Early, mid, and late-stage investments are made in science sectors.
|
Locked | Locked | Locked |
Investor details for Biomodal
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biomodal
Investment portfolio details for Biomodal
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biomodal
Detailed financials for Biomodal
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomodal Comparisons
Peer comparison for Biomodal
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biomodal
Biomodal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aligned Bio, Singular Bio, YouScript, Nooma Bio and Annogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanowire-based sensors and alignment technologies are provided for molecular detection.
|
|
| Locked | Locked | Locked |
Tools for single molecule detection are developed by Singular Bio.
|
|
| Locked | Locked | Locked |
Clinical decision support software for drug interactions is developed.
|
|
| Locked | Locked | Locked |
Dual-nanopore technology is developed for genome-wide structural and epigenetic variations.
|
|
| Locked | Locked | Locked |
Genetic variations are screened via a specialized genomic platform.
|
Detailed competitors of Biomodal
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomodal
Complete news archive for Biomodal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biomodal
Biomodal was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Biomodal is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Peter Fromen is the current CEO of Biomodal.
Biomodal is a funded company, having raised a total of $164.1M across 5 funding rounds to date.
Biomodal was founded in 2012 in Cambridge, United Kingdom, within the biotechnology sector. DNA sequencing tools and technologies are developed by the company for research and diagnostic applications. A duet multi-omics solution, including modC, is provided, which employs next-generation sequencing to obtain genetic and epigenetic methylation data. These tools support areas such as cancer research, non-invasive prenatal testing, and precision medicine.
Biomodal's top competitors include Aligned Bio, Singular Bio and YouScript.
Biomodal offers duet multiomics solution evoC and duet multiomics solution +modC.
Biomodal has 10 investors. Key investors include Syncona, Temasek, European Union, University of Cambridge, and Third Point.
The valuation of Biomodal is $163.5M as of Apr 2018.